Steady Augmentation of Anti-Osteoarthritic Actions of Rapamycin by Liposome-Encapsulation in Collaboration with Low-Intensity Pulsed Ultrasound [Corrigendum]

This article refers to:

Steady Augmentation of Anti-Osteoarthritic Actions of Rapamycin by Liposome-Encapsulation in Collaboration with Low-Intensity Pulsed Ultrasound

Chen CH, Kuo SM, Tien YC, Shen PC, Kuo YW, Huang HH. Int J Nanomedicine. 2020;15:3771–3790.

The authors have advised due to an error at the time of figure assembly, Figure 2B on page 3778 is incorrect. The correct Figure 2 is shown below.

Figure 2 (A) Pure rapamycin at 20 nM decreased human normal chondrocyte proliferation by about 15% while (B) pure rapamycin and L-rapa with or without LIPUS did not cause significant effects on HOAC proliferation. (C) L-rapa at 20 nM and 2 nM in collaboration with LIPUS approximately doubled proteoglycan production in human normal chondrocytes cultured in alginate beads. (D) L-rapa at 2 nM alone and in combination with LIPUS increased type II collagen production by around 1.7-folds in human normal chondrocytes cultured in alginate beads (PG: proteoglycan; **P<0.01; ***P<0.001; by one-way ANOVA, N=5).

The authors apologize for this error and advise it does not affect the results of the paper.